BR112016004324A2 - anticorpos - Google Patents

anticorpos

Info

Publication number
BR112016004324A2
BR112016004324A2 BR112016004324A BR112016004324A BR112016004324A2 BR 112016004324 A2 BR112016004324 A2 BR 112016004324A2 BR 112016004324 A BR112016004324 A BR 112016004324A BR 112016004324 A BR112016004324 A BR 112016004324A BR 112016004324 A2 BR112016004324 A2 BR 112016004324A2
Authority
BR
Brazil
Prior art keywords
antibody
binding fragment
same
present
antibodies
Prior art date
Application number
BR112016004324A
Other languages
English (en)
Other versions
BR112016004324B1 (pt
Inventor
Marshall Diane
Craggs Graham
Jeannine Madeleine Hervé Karine
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016004324(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112016004324A2 publication Critical patent/BR112016004324A2/pt
Publication of BR112016004324B1 publication Critical patent/BR112016004324B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

a presente invenção diz respeito a um anticorpo anti-csf-1r e fragmentos de ligação do mesmo, dna que codifica o mesmo, células hospedeiras compreendendo o dito dna e métodos de expressar o anticorpo ou fragmento de ligação em uma célula hospedeira. a presente invenção também se estende às composições farmacêuticas compreendendo o anticorpo ou um fragmento de ligação do mesmo e ao uso do anticorpo, fragmento de ligação e composições compreendendo o mesmo no tratamento.
BR112016004324-3A 2013-08-30 2014-08-26 Anticorpos anti-csf-1r, vetor e composição farmacêutica BR112016004324B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies
GB1315487.7 2013-08-30
PCT/EP2014/068050 WO2015028455A1 (en) 2013-08-30 2014-08-26 Antibodies

Publications (2)

Publication Number Publication Date
BR112016004324A2 true BR112016004324A2 (pt) 2017-10-24
BR112016004324B1 BR112016004324B1 (pt) 2024-01-16

Family

ID=49397073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004324-3A BR112016004324B1 (pt) 2013-08-30 2014-08-26 Anticorpos anti-csf-1r, vetor e composição farmacêutica

Country Status (39)

Country Link
US (2) US9908939B2 (pt)
EP (3) EP3549599B1 (pt)
JP (3) JP6632075B2 (pt)
KR (1) KR102303130B1 (pt)
CN (2) CN112321711A (pt)
AR (1) AR097464A1 (pt)
AU (1) AU2014314304B2 (pt)
BR (1) BR112016004324B1 (pt)
CA (1) CA2922240C (pt)
CL (1) CL2016000438A1 (pt)
CY (1) CY1121964T1 (pt)
DK (2) DK3549599T3 (pt)
EA (1) EA036255B1 (pt)
ES (2) ES2733735T3 (pt)
FI (1) FI3549599T3 (pt)
GB (1) GB201315487D0 (pt)
HK (1) HK1220142A1 (pt)
HR (2) HRP20231264T1 (pt)
HU (2) HUE064437T2 (pt)
IL (1) IL244043B (pt)
LT (2) LT3038643T (pt)
MA (2) MA44922B1 (pt)
MX (1) MX2016002166A (pt)
MY (1) MY172484A (pt)
NZ (1) NZ717399A (pt)
PE (2) PE20201067A1 (pt)
PH (1) PH12016500275A1 (pt)
PL (2) PL3549599T3 (pt)
PT (2) PT3038643T (pt)
RS (2) RS59019B1 (pt)
SG (1) SG11201601151PA (pt)
SI (2) SI3549599T1 (pt)
TN (1) TN2016000067A1 (pt)
TR (1) TR201909478T4 (pt)
TW (1) TWI531582B (pt)
UA (1) UA118354C2 (pt)
UY (1) UY35718A (pt)
WO (1) WO2015028455A1 (pt)
ZA (1) ZA201601437B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
MA47395A (fr) * 2015-05-27 2019-12-11 Ucb Biopharma Sprl Méthode pour le traitement d'une maladie neurologique
JP2018516933A (ja) * 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
KR20240042244A (ko) * 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
TWI733274B (zh) * 2018-12-13 2021-07-11 財團法人生物技術開發中心 抗人類csf-1r抗體及其用途
WO2020232051A1 (en) * 2019-05-15 2020-11-19 Biosion Inc. Antibody binding csf-1r and use thereof
KR20220117320A (ko) * 2019-12-24 2022-08-23 아다젠 (수저우) 리미티드 항 csf1r 분자 및 이의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN102164965B (zh) 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
SI2949670T1 (sl) * 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2011107553A1 (en) * 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
TWI713942B (zh) * 2010-05-04 2020-12-21 美商戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
MX356337B (es) * 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
PH12016500275B1 (en) 2016-05-02
MY172484A (en) 2019-11-26
RS59019B1 (sr) 2019-08-30
HUE064437T2 (hu) 2024-03-28
US10421814B2 (en) 2019-09-24
DK3549599T3 (en) 2023-10-30
JP7195237B2 (ja) 2022-12-23
AU2014314304A1 (en) 2016-03-17
ZA201601437B (en) 2018-08-29
TN2016000067A1 (en) 2017-07-05
US20180162947A1 (en) 2018-06-14
MA44922A1 (fr) 2019-08-30
HUE045672T2 (hu) 2020-01-28
EP3549599B1 (en) 2023-09-06
EP3038643B1 (en) 2019-05-01
SI3549599T1 (sl) 2023-12-29
RS64784B1 (sr) 2023-11-30
TW201512221A (zh) 2015-04-01
EP4282881A3 (en) 2024-02-21
JP2020005652A (ja) 2020-01-16
CN105658236A (zh) 2016-06-08
PE20201067A1 (es) 2020-10-19
EP3549599A1 (en) 2019-10-09
TR201909478T4 (tr) 2019-07-22
AR097464A1 (es) 2016-03-16
HRP20191051T1 (hr) 2019-09-06
DK3038643T3 (da) 2019-06-24
US20160200821A1 (en) 2016-07-14
SG11201601151PA (en) 2016-03-30
NZ717399A (en) 2021-12-24
EP4282881A2 (en) 2023-11-29
JP6632075B2 (ja) 2020-01-15
UY35718A (es) 2015-03-27
SI3038643T1 (sl) 2019-08-30
IL244043B (en) 2021-01-31
LT3038643T (lt) 2019-07-25
KR102303130B1 (ko) 2021-09-16
ES2733735T3 (es) 2019-12-02
AU2014314304B2 (en) 2019-12-05
PT3038643T (pt) 2019-07-25
CA2922240A1 (en) 2015-03-05
JP2016529266A (ja) 2016-09-23
JP2022002523A (ja) 2022-01-11
MX2016002166A (es) 2016-06-23
PE20160528A1 (es) 2016-05-21
MA44922B1 (fr) 2020-06-30
EA036255B1 (ru) 2020-10-20
PL3549599T3 (pl) 2024-03-04
BR112016004324B1 (pt) 2024-01-16
CY1121964T1 (el) 2020-10-14
PH12016500275A1 (en) 2016-05-02
CN105658236B (zh) 2021-03-19
KR20160044018A (ko) 2016-04-22
HK1220142A1 (zh) 2017-04-28
HRP20231264T1 (hr) 2024-02-02
GB201315487D0 (en) 2013-10-16
ES2965207T3 (es) 2024-04-11
UA118354C2 (uk) 2019-01-10
US9908939B2 (en) 2018-03-06
IL244043A0 (en) 2016-04-21
TWI531582B (zh) 2016-05-01
EP3038643A1 (en) 2016-07-06
EA201690503A1 (ru) 2016-06-30
CN112321711A (zh) 2021-02-05
FI3549599T3 (fi) 2023-10-31
PT3549599T (pt) 2023-11-21
CL2016000438A1 (es) 2016-11-11
WO2015028455A1 (en) 2015-03-05
CA2922240C (en) 2023-09-05
MA38930A1 (fr) 2017-12-29
PL3038643T3 (pl) 2019-11-29
LT3549599T (lt) 2023-11-10

Similar Documents

Publication Publication Date Title
BR112016004324A2 (pt) anticorpos
CY1121934T1 (el) Αντισωματα anti-fcrn
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CL2011002003A1 (es) Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
UY35286A (es) Construcciones de anticuerpos para CDH19 y CD3
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
CO6630164A2 (es) Proteinas que se unen al tnf-a
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA201892774A1 (ru) Антитела
ECSP14020402A (es) Polipéptidos de unión a cx3cr1
PH12015501687A1 (en) Novel binding proteins from pcsk9
BR112017023131A2 (pt) anticorpos anti- fcrn
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112017001782A2 (pt) fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
BR112016002619A2 (pt) “moléculas de ligação do receptor de bag3 para o uso como um medicamento”
BR112015023429A8 (pt) anticorpos pac1 humanos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023009982-6 PROTOCOLO 870230043235 EM 23/05/2023 15:01.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/08/2014, OBSERVADAS AS CONDICOES LEGAIS